[go: up one dir, main page]

MX2012013374A - Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. - Google Patents

Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.

Info

Publication number
MX2012013374A
MX2012013374A MX2012013374A MX2012013374A MX2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A
Authority
MX
Mexico
Prior art keywords
clostridium difficile
treatment
antibiotic therapy
difficile infection
patients undergoing
Prior art date
Application number
MX2012013374A
Other languages
English (en)
Inventor
Youe-Kong Shue
Pamela Sears
Sherwood Gorbach
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012013374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of MX2012013374A publication Critical patent/MX2012013374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Métodos para tratar una infección de Clostridium difficile en un sujeto que está recibiendo una terapia con antibióticos para combatir una infección diferente, que comprenden administrarle al sujeto una cantidad eficaz de un compuesto como los que se describen en la presente.
MX2012013374A 2010-05-18 2011-05-18 Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. MX2012013374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34591510P 2010-05-18 2010-05-18
PCT/US2011/037003 WO2011146621A2 (en) 2010-05-18 2011-05-18 Treatment of clostridium difficile infection in patients undergoing antibiotic therapy

Publications (1)

Publication Number Publication Date
MX2012013374A true MX2012013374A (es) 2013-05-06

Family

ID=44992319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013374A MX2012013374A (es) 2010-05-18 2011-05-18 Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.

Country Status (9)

Country Link
US (1) US20130331347A1 (es)
AU (1) AU2011255630B2 (es)
BR (1) BR112012029259A8 (es)
CA (1) CA2799386A1 (es)
CL (1) CL2012003201A1 (es)
CO (1) CO6670518A2 (es)
MX (1) MX2012013374A (es)
PE (1) PE20130310A1 (es)
WO (1) WO2011146621A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140024609A1 (en) * 2011-02-04 2014-01-23 Optimer Pharmaceuticals ,Inc. Treatment of Bacterial Infections
WO2014135891A1 (en) * 2013-03-08 2014-09-12 Cipla Limited Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103920017B (zh) * 2014-05-09 2016-08-17 马金风 一种治疗宫颈炎的药物组合物
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2070530T3 (pl) * 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
CA2799386A1 (en) 2011-11-24
WO2011146621A2 (en) 2011-11-24
US20130331347A1 (en) 2013-12-12
CO6670518A2 (es) 2013-05-15
BR112012029259A2 (pt) 2021-03-02
WO2011146621A9 (en) 2012-04-12
PE20130310A1 (es) 2013-04-06
CL2012003201A1 (es) 2013-07-05
BR112012029259A8 (pt) 2021-03-23
AU2011255630B2 (en) 2015-04-30
AU2011255630A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
AU2011328009A8 (en) Compounds and methods for treating pain
PH12013501688A1 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12015500954B1 (en) Device for extracorporeal blood treatment
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
MX2013009256A (es) Metodo para inhibir las celulas tumorales hamartoma.
PH12013500857A1 (en) Methods and compositions for treating hiv-associated diarrhea
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
MX2012013374A (es) Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
PH12014502065A1 (en) Vesicular formulations
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
WO2011133826A3 (en) Method for treating pancreatic cancer
MX2012013372A (es) Metodos para tratar infecciones bacterianas recurrentes.
PH12014500973A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
WO2012075210A3 (en) Method for treating refractory cancer
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
UA71871U (ru) Способ диагностики эффективности антибиотикотерапии у больных лайм-борелиозом
UA105429C2 (ru) Способ лечения опухолевых образований
UA46514U (ru) Способ местного лечения ограниченной склеродермии

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: SOLENIS TECHNOLOGIES CAYMAN, L.P.

FA Abandonment or withdrawal